198 results
8-K
EX-99.1
BPTH
Bio-Path Holdings Inc
15 May 24
Bio-Path Holdings Reports First Quarter 2024 Financial Results
7:10am
. ET to review these first quarter 2024 financial results and to provide a general update on the Company. To access the conference call please dial (844
424B5
BPTH
Bio-Path Holdings Inc
19 Apr 24
Prospectus supplement for primary offering
3:28pm
common stock could materially adversely affect our access to the capital markets and any limitation on liquidity or reduction in the price of our common
8-K
EX-10.1
BPTH
Bio-Path Holdings Inc
19 Apr 24
Bio-Path Holdings, Inc. Announces $1.2 Million Registered Direct Offering Priced At-the- Market Under Nasdaq Rules
9:21am
statements in conformity with GAAP and to maintain asset accountability, (iii) access to assets is permitted only in accordance with management’s general … and to the protection of such IT Systems and Data from unauthorized use, access, misappropriation or modification, except as would not, individually
424B5
841r9
19 Apr 24
Prospectus supplement for primary offering
9:17am
8-K
EX-10.1
s90ip6cee3y
4 Apr 24
Entry into a Material Definitive Agreement
4:35pm
424B5
ygu46c3 nmtjyt
4 Apr 24
Prospectus supplement for primary offering
4:33pm
424B5
k075lzc449xx hu
27 Mar 24
Prospectus supplement for primary offering
8:15am
8-K
EX-10.1
erg0 me0olizzprr
26 Mar 24
Entry into a Material Definitive Agreement
8:03am
8-K
EX-99.1
tuen14 oez13w11e
8 Mar 24
Bio-path Holdings Reports Full Year 2023 Financial Results
7:10am
8-K
EX-99.1
v595jnwdt2k5d4k8
10 Jan 24
Targeting Bcl-2 Protein Offers Potential Treatment for Patients Who Have Failed or Relapsed from Venetoclax-Based Frontline Therapy
4:10pm